scholarly journals Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied

2020 ◽  
Vol 222 (6) ◽  
pp. 948-956 ◽  
Author(s):  
Simopekka Vänskä ◽  
Tapio Luostarinen ◽  
Iacopo Baussano ◽  
Dan Apter ◽  
Tiina Eriksson ◽  
...  
Keyword(s):  
Hpv Vaccination ◽  
Vaccination Strategy ◽  
Human Papillomaviruses ◽  
Birth Cohorts ◽  
High Coverage ◽  
Herd Effect ◽  
B Virus ◽  
Gender Neutral ◽  
Very High ◽  
Protective Effectiveness

Abstract Background Human papillomavirus (HPV) vaccination of girls with very high (>90%) coverage has the potential to eradicate oncogenic HPVs, but such high coverage is hard to achieve. However, the herd effect (HE) depends both on the HPV type and the vaccination strategy. Methods We randomized 33 Finnish communities into gender-neutral HPV16/18 vaccination, girls-only HPV16/18 vaccination, and hepatitis B virus vaccination arms. In 2007–2010, 11 662 of 20 513 of 40 852 of 39 420 resident boys/girls from 1992 to 1995 birth cohorts consented. In 2010–2014, cervicovaginal samples from vaccinated and unvaccinated girls at age 18.5 years were typed for HPV6/11/16/18/31/33/35/39/45/51/52/56/58/59/66/68. Vaccine efficacy for vaccinated girls, HE for unvaccinated girls, and the protective effectiveness (PE) for all girls were estimated. We extended the community-randomized trial results about vaccination strategy with mathematical modeling to assess HPV eradication. Results The HE and PE estimates in the 1995 birth cohort for HPV18/31/33 were significant in the gender-neutral arm and 150% and 40% stronger than in the girls-only arm. Concordantly, HPV18/31/33 eradication was already predicted in adolescents/young adults in 20 years with 75% coverage of gender-neutral vaccination. With the 75% coverage, eventual HPV16 eradication was also predicted, but only with the gender-neutral strategy. Conclusions Gender-neutral vaccination is superior for eradication of oncogenic HPVs.

scholarly journals Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial

PLoS Medicine ◽  
2021 ◽  
Vol 18 (6) ◽  
pp. e1003588
Author(s):  
Penelope Gray ◽  
Hanna Kann ◽  
Ville N. Pimenoff ◽  
Tiina Eriksson ◽  
Tapio Luostarinen ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Randomized Trial ◽  
Vaccination Coverage ◽  
Hpv Vaccination ◽  
Herd Effect ◽  
Entire Study ◽  
Post Vaccination ◽  
Vaccination Programs ◽  
Link Type ◽  
Gender Neutral

Background Cervical cancer elimination through human papillomavirus (HPV) vaccination programs requires the attainment of herd effect. Due to its uniquely high basic reproduction number, the vaccination coverage required to achieve herd effect against HPV type 16 exceeds what is attainable in most populations. We have compared how gender-neutral and girls-only vaccination strategies create herd effect against HPV16 under moderate vaccination coverage achieved in a population-based, community-randomized trial. Methods and findings In 2007–2010, the 1992–1995 birth cohorts of 33 Finnish communities were randomized to receive gender-neutral HPV vaccination (Arm A), girls-only HPV vaccination (Arm B), or no HPV vaccination (Arm C) (11 communities per trial arm). HPV16/18/31/33/35/45 seroprevalence differences between the pre-vaccination era (2005–2010) and post-vaccination era (2011–2016) were compared between all 8,022 unvaccinated women <23 years old and resident in the 33 communities during 2005–2016 (2,657, 2,691, and 2,674 in Arms A, B, and C, respectively). Post- versus pre-vaccination-era HPV seroprevalence ratios (PRs) were compared by arm. Possible outcome misclassification was quantified via probabilistic bias analysis. An HPV16 and HPV18 seroprevalence reduction was observed post-vaccination in the gender-neutral vaccination arm in the entire study population (PR16 = 0.64, 95% CI 0.10–0.85; PR18 = 0.72, 95% CI 0.22–0.96) and for HPV16 also in the herpes simplex virus type 2 seropositive core group (PR16 = 0.64, 95% CI 0.50–0.81). Observed reductions in HPV31/33/35/45 seroprevalence (PR31/33/35/45 = 0.88, 95% CI 0.81–0.97) were replicated in Arm C (PR31/33/35/45 = 0.79, 95% CI 0.69–0.90). Conclusions In this study we only observed herd effect against HPV16/18 after gender-neutral vaccination with moderate vaccination coverage. With only moderate vaccination coverage, a gender-neutral vaccination strategy can facilitate the control of even HPV16. Our findings may have limited transportability to other vaccination coverage levels. Trial registration ClinicalTrials.gov number NCT00534638, https://clinicaltrials.gov/ct2/show/NCT00534638.

scholarly journals Benefits of Gender-Neutral Vaccination Strategy for the Prevention of HPV-Associated Diseases and the Eradication of HPV Infection in General. Current State of HPV Vaccination in the World

2021 ◽  
Vol 18 (3) ◽  
pp. 239-244
Author(s):  
Tatiana E. Privalova ◽  
Olga V. Surovtseva ◽  
Dmitry V. Andriyanov
Keyword(s):  
Hpv Vaccination ◽  
Vaccination Strategy ◽  
Hpv Infection ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Associated Diseases ◽  
Current State ◽  
Papillomavirus Infection ◽  
The World ◽  
Gender Neutral

Papillomavirus infection (HPV infection) is the leading sexually transmitted infection in prevalence. HPV infection and associated diseases, including cancer, remain one of the global problems of our time. This literature review presents relevant data from foreign studies and domestic works on the state of HPV vaccination in the world, the modern vaccines efficacy for the HPV-associated diseases prevention, current vaccination strategies and their efficacy as well. The aim of the article is to determine the advantages of using gender-neutral vaccination strategy over priority-used vaccination strategy for girls only in the prevention of HPV-associated diseases, including cancer, as well as for eradicating HPV infection in general.

scholarly journals Persistence of rubella and mumps antibodies, following changes in the recommended age for the second dose of MMR vaccine in Portugal

2016 ◽  
Vol 144 (15) ◽  
pp. 3139-3147 ◽  
Author(s):  
G. GONÇALVES ◽  
J. FRADE ◽  
M. S. J. NASCIMENTO ◽  
J. R. MESQUITA ◽  
C. NUNES
Keyword(s):  
Geometric Mean ◽  
Igg Antibodies ◽  
Birth Cohorts ◽  
Mmr Vaccine ◽  
High Coverage ◽  
Previous Evidence ◽  
Specific Antibodies ◽  
Mumps Antibodies ◽  
Very High

SUMMARYIn Portugal, the recommended age for the second dose of MMR (MMR2) was changed from 10–13 years to 5–6 years for those born in 1994 and afterwards. This study aimed to assess if MMR schedule and time elapsed from the last dose are associated with the concentration of rubella and mumps IgG antibodies. Three Portuguese birth cohorts (convenience samples) were selected for this study (66, 59 and 41 participants born respectively in 1990–1993, 1994–1995 and 2001–2003). Geometric mean concentrations (GMC) for mumps IgG were respectively 36, 30 and 38 RU/ml (P = 0·236) and for rubella IgG were 18, 20 and 17 IU/ml (P = 0·641). For both specific antibodies, no differences were observed with time since MMR2. Receiving MMR2 at 5–6 or 10–13 years was not associated with concentration of both antibodies. The GMC of rubella IgG was lower in males (P = 0·029). Taking into account previous evidence and the logistics needed to change vaccination schedules, it seems reasonable that sustaining very high coverage with two doses of MMR is currently the most pragmatic way to control mumps and rubella rather than any changes to the schedule.

Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017

2019 ◽  
Vol 95 (5) ◽  
pp. 368-373 ◽  
Author(s):  
Marta Checchi ◽  
David Mesher ◽  
Hamish Mohammed ◽  
Kate Soldan
Keyword(s):  
Vaccination Programme ◽  
Hpv Vaccination ◽  
Quadrivalent Vaccine ◽  
Birth Cohorts ◽  
Anogenital Warts ◽  
High Coverage ◽  
Bivalent Vaccine ◽  
Young Females ◽  
Sexual Health Clinics ◽  
The Impact

ObjectivesIn 2008, a national human papillomavirus (HPV) vaccination programme for females was introduced in England using the bivalent vaccine (HPV16 and 18 only). In 2012, the programme changed to offer the quadrivalent vaccine that includes protection against the two HPV types that cause the majority of anogenital warts (AGW; HPV6 and 11). We present data reporting AGW diagnoses in sexual health clinics (SHCs) in England to the end of 2017, including diagnoses among birth cohorts offered the quadrivalent vaccine.MethodsUsing data from all SHCs across England, we performed ecological analyses to consider rates of AGW diagnoses by age, gender and sexual orientation. We tested for trends over time of diagnoses of AGW in young females, heterosexual males, and men who have sex with men (MSM) between the ages of 15 and 24 years during both bivalent (2009 to 2013) and quadrivalent (2014 to 2017) vaccine time periods using Poisson regression.ResultsBetween 2014 and 2017, there was strong evidence for a decreasing trend in the rate of AGW diagnoses at SHC among females aged 15–17 years from 257.5 to 45.7 per 100 000 population (82.3% decline) and same aged heterosexual males from 59.1 to 19.1 per 100 000 population (67.7% decline). The reductions in the incidence of AGW diagnoses in MSM aged 15–17 years were less clear (decreased by 13.6% between 2014 and 2017, from 129.9 to 112.2 per 100 000 population).ConclusionsThe moderate, unexpected declines in AGW seen since the introduction of a high-coverage HPV vaccination programme using the bivalent vaccine are being followed, as expected, by much larger declines among females offered the quadrivalent vaccine and same-aged heterosexual males. Surveillance plans are in place to continue to monitor AGW diagnoses to evaluate the impact of both female and targeted MSM HPV vaccination on early disease outcomes.

Papillomavirus infection and reproduction

2020 ◽  
Vol 75 (3) ◽  
pp. 189-195
Author(s):  
Vladislav I. Krasnopolsky ◽  
Nina V. Zarochentseva ◽  
Ksenia V. Krasnopolskaya ◽  
Yulia N. Bashankaeva ◽  
Varvara S. Kuzmicheva
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccination ◽  
Carcinogenic Risk ◽  
Human Papillomaviruses ◽  
World Health ◽  
Sexually Transmitted ◽  
Associated Diseases ◽  
Trophoblastic Cells ◽  
Papillomavirus Infection ◽  
Health Organization

The purpose of the review a synthesis of research data on the role of human papillomavirus infection in the reproductive health of women and men. Key Points. Human papillomavirus (HPV) is one of the most common sexually transmitted viruses worldwide. According to the World Health Organization, HPV is the main cause of the development of HPV-associated diseases among both women and men. Viruses are subdivided into HPV with low carcinogenic risk, which cause benign warts, and HPV with high carcinogenic risk, which cause cancer. Different types of human papillomaviruses depending on their characteristic tropism, are divided into skin and mucous types. Viral infection in men leads to a decrease in the quality of sperm (for example, asthenozoospermia) due to apoptosis in sperm cells and due to the development of antisperm immunity. A negative viral effect on the fertility of women is manifested in an increase in the frequency of spontaneous miscarriages and a premature rupture of the amniotic membranes during pregnancy. There is evidence that HPV decreases the number of trophoblastic cells and abnormal trophoblastic-endometrial adhesion is also observed. In trophoblastic cells transfected with high-risk HPV, the level of apoptosis increases. HPV vaccination is safe, and the results show not only protection against HPV-associated diseases in women and men, but also a reduction of gestational complications, reduced preterm birth rates and the protection of newborns from infection.

scholarly journals Rotavirus Vaccination of Infants Delayed and Limited within the National Immunization Programme in the Netherlands: An Opportunity Lost

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 144
Author(s):  
Florian Zeevat ◽  
Evgeni Dvortsin ◽  
Abrham Wondimu ◽  
Jan C. Wilschut ◽  
Cornelis Boersma ◽  
...  
Keyword(s):  
High Risk ◽  
The Netherlands ◽  
Herd Immunity ◽  
Vaccination Strategy ◽  
Quality Adjusted Life Year ◽  
High Risk Group ◽  
Universal Vaccination ◽  
Birth Cohorts ◽  
Rotavirus Vaccination ◽  
Immunization Programme

In this study, we estimated the benefits of rotavirus vaccination for infants had the rotavirus vaccine been introduced in the Netherlands as of its market authorization in 2006. An age-structured, deterministic cohort model was developed to simulate different birth cohorts over a period of 15 years from 2006 until 2021, comparing both universal and targeted high-risk group vaccination to no vaccination. Different scenarios for the duration of protection (5 or 7 years) and herd immunity (only for universal vaccination) were analyzed. All birth cohorts together included 2.6 million infants, of which 7.9% were high-risk individuals, and an additional 13.2 million children between 1–15 years born prior to the first cohort in 2006. The costs and health outcomes associated with rotavirus vaccination were calculated per model scenario and discounted at 4% and 1.5%, respectively. Our analysis reveals that, had rotavirus vaccination been implemented in 2006, it would have prevented 356,800 (51% decrease) and 32,200 (5% decrease) cases of rotavirus gastroenteritis after universal and targeted vaccination, respectively. Over the last 15 years, this would have led to significant avoided costs and quality-adjusted life year losses for either vaccination strategy with the most favorable outcomes for universal vaccination. Clearly, an opportunity has been lost.

Cost Effective Swath Bathymetry

2001 ◽  
Vol 35 (4) ◽  
pp. 33-45 ◽  
Author(s):  
Peter Hogarth
Keyword(s):  
Processing Time ◽  
Cost Effective ◽  
High Accuracy ◽  
High Coverage ◽  
Swath Bathymetry ◽  
World Survey ◽  
Set Up ◽  
Very High ◽  
Harbor Area ◽  
Wide Swath

Between 23rd and 25th July 2001 GeoSwath, a high specification shallow water wide swath bathymetry system, was used to survey the entire Portsmouth NH Harbor area. This paper deals with the results of this survey, illustrating the potential for significant reductions in the high costs, which have prevented widespread proliferation of Swath Bathymetry systems to date. Data, including a complete DTM gridded to 1 m resolution, will be presented and discussed in detail. These results show that the system is very easy to set up and use, requires greatly reduced boat and processing time, whilst offering high accuracy and very high coverage and resolution when used in a real-world survey of a dynamic harbor environment.

scholarly journals Economic evaluation of options for measles vaccination strategy in a hypothetical Western European country

2003 ◽  
Vol 130 (2) ◽  
pp. 273-283 ◽  
Author(s):  
Ph. BEUTELS ◽  
N. J. GAY
Keyword(s):  
Health Care ◽  
European Country ◽  
Vaccination Coverage ◽  
Vaccination Strategy ◽  
Western European Country ◽  
High Coverage ◽  
The Past ◽  
Care Payer ◽  
Measles Vaccination ◽  
Western European

In this study an analysis was made of economic costs and medical effects (by cost-effectiveness and cost–benefit analysis) associated with measles vaccination in a hypothetical Western European country. We analysed ten vaccination options in terms of past and future vaccination coverage. We show that several of the proposed strategies for improving measles vaccination coverage are preferable to maintaining the existing policies, regardless of past coverage and the viewpoint of the analysis. For society, very high coverage (95%) two-dose vaccination is most optimal, irrespective of past vaccination coverage. The addition of a one-time campaign (to reduce susceptibility in (pre-)adolescent age groups) to such a high coverage two-dose vaccination programme is cost-saving to the health-care payer and to society when coverage in the past was low ([les ]70%). Even when coverage in the past was high (90%) for more than a decade, this ‘maximum strategy’ could be implemented at an acceptable cost to the health-care payer (incremental direct costs per discounted life-year gained <€30000), and at net savings to society.

scholarly journals Acceptability and feasibility of human papillomavirus vaccination for adolescents in school environments in Libreville

2020 ◽  
Vol 9 (9) ◽  
pp. 3541
Author(s):  
Nathalie L. Ambounda ◽  
Sylvain H. Woromogo ◽  
Olive M. Kenmogne ◽  
Felicite E. Yagata Moussa ◽  
Vicky N. Simo Tekem ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
High Risk ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Immunization Coverage ◽  
Human Papillomaviruses ◽  
Professional Status ◽  
Human Papillomavirus Vaccination ◽  
Cross Sectional

Background: High-risk oncogenic human papillomaviruses (HPV) are the cause of sexually transmitted viral infection. Its persistence is a risk factor for precancerous lesions of the cervix, which will constitute the base of cervical cancer. In the world, the prevalence of high-risk oncogenic HPV is 66.7%, which is higher among women starting their sexual activity.Methods: An analytical cross-sectional study was conducted in high schools in Gabon regarding parents. The variables selected were the socio-cultural and demographic characteristics of the parents, their knowledge of human papillomavirus vaccination and their acceptability of HPV vaccination and finally the feasibility of HPV vaccination. The statistical test used was Pearson's Chi-square, and a difference was considered significant for p<0.05.Results: The majority of parents, 89%, were informed of the existence of cervical cancer. However, 73.4% of them were unaware of the existence of vaccination against cervical cancer. Only 2.4% of parents had vaccinated their daughters against cervical cancer at the time of the study. These parents only 53.4% expressed an interest in vaccinating their daughters in 53.4% of cases. The ability to vaccinate children is associated with the socio-professional status of parents (p˂0.000).Conclusions: The majority of parents approved school-based vaccination against human papillomavirus infections despite its reported cost and lack of information. The integration of anti-HPV vaccination into the expanded programme on immunization in Gabon will improve immunization coverage.

Targeted Long-Read Sequencing Reveals Comprehensive Architecture, Burden and Transcriptional Signatures from HBV-Associated Integrations and Translocations in HCC Cell Lines

2021 ◽  
Author(s):  
Ricardo Ramirez ◽  
Nicholas van Buuren ◽  
Lindsay Gamelin ◽  
Cameron Soulette ◽  
Lindsey May ◽  
...  
Keyword(s):  
Cell Lines ◽  
Transcriptional Activity ◽  
Hbv Dna ◽  
Chromosomal Translocations ◽  
Sequencing Data ◽  
High Coverage ◽  
B Virus ◽  
Long Read ◽  
Custom Panel ◽  
Viral Sequences

Hepatitis B virus (HBV) can integrate into the chromosomes of infected hepatocytes, creating potentially oncogenic lesions that can lead to hepatocellular carcinoma (HCC). However, our current understanding of integrated HBV DNA architecture, burden and transcriptional activity is incomplete due to technical limitations. A combination of genomics approaches was used to describe HBV integrations and corresponding transcriptional signatures in three HCC cell lines: huH-1, PLC/PRF/5 and Hep3B. To generate high coverage long-read sequencing data, a custom panel of HBV-targeting biotinylated oligonucleotide probes was designed. Targeted long-read DNA sequencing captured entire HBV integration events within individual reads, revealing that integrations may include deletions and inversions of viral sequences. Surprisingly, all three HCC cell lines contain integrations that are associated with host chromosomal translocations. In addition, targeted long-read RNA sequencing allowed for the assignment of transcriptional activity to specific integrations and resolved the contribution of overlapping HBV transcripts. HBV transcripts chimeric with host sequences were resolved in their entirety and often included >1000bp of host sequence. This study provides the first comprehensive description of HBV integrations and associated transcriptional activity in three commonly utilized HCC-derived cell lines. The application of novel methods sheds new light on the complexity of these integrations, including HBV bidirectional transcription, nested transcripts, silent integrations and host genomic rearrangements. The observation of multiple HBV-associated chromosomal translocations gives rise to the hypothesis that HBV may be a driver of genetic instability and provides a potential new mechanism for HCC development. Importance HCC-derived cell lines have served as practical models to study HBV biology for decades. These cell lines harbor multiple HBV integrations and express only HBV surface antigen (HBsAg). To date, an accurate description of the integration burden, architecture and transcriptional profile of these cell lines has been limited due to technical constraints. We have developed a targeted long-read sequencing assay which reveals the entire architecture of integrations in these cell lines. In addition, we identified five chromosomal translocations with integrated HBV DNA at the inter-chromosomal junctions. Incorporation of long-read RNA-Seq data indicated that many integrations and translocations were transcriptionally silent. The observation of multiple HBV-associated translocations has strong implications regarding the potential mechanisms for the development of HBV-associated HCC.

Sign in / Sign up

Export Citation Format

Share Document